Altamira Therapeutics Ltd.

Symbol: CYTO




Market price today

  • -0.0459

    P/E Ratio

  • -0.0024

    PEG Ratio

  • 3.36M

    MRK Cap

  • 0.00%

    DIV Yield

Altamira Therapeutics Ltd. (CYTO) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Thomas Meyer Ph.D.
Full-time employees:10
Address:Clarendon House

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

General Outlook

When we look at how much money they make before expenses, they keep -1.012% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 12.691%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -59.004%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.809% return, is a testament to Altamira Therapeutics Ltd.'s adeptness in optimizing resource deployment. Altamira Therapeutics Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.686%. Furthermore, the proficiency of Altamira Therapeutics Ltd. in capital utilization is underscored by a remarkable 0.197% return on capital employed.

Stock Prices

Altamira Therapeutics Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.67, while its low point bottomed out at $1.53. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Altamira Therapeutics Ltd.'s stock market.

Liquidity Ratios

Analyzing CYTO liquidity ratios reveals its financial health of the firm. The current ratio of 137.60% gauges short-term asset coverage for liabilities. The quick ratio (77.87%) assesses immediate liquidity, while the cash ratio (69.46%) indicates cash reserves.

Current Ratio137.60%
Quick Ratio77.87%
Cash Ratio69.46%

Profitability Ratios

CYTO profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -5871.09% underscores its earnings before tax deductions. The effective tax rate stands at -0.50%, revealing its tax efficiency. The net income per EBT, 100.50%, and the EBT per EBIT, -462.62%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 1269.10%, we grasp its operational profitability.

Pretax Profit Margin-5871.09%
Effective Tax Rate-0.50%
Net Income per EBT100.50%
EBT per EBIT-462.62%
EBIT per Revenue1269.10%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.38, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 140.96% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding78
Days of Inventory Outstanding-129
Operating Cycle130.23
Days of Payables Outstanding711
Cash Conversion Cycle-580
Receivables Turnover1.41
Payables Turnover0.51
Inventory Turnover-2.84
Fixed Asset Turnover1.32
Asset Turnover0.01

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -44.13, and free cash flow per share, -44.13, depict cash generation on a per-share basis. The cash per share value, 2.94, showcases liquidity position. Lastly, the operating cash flow sales ratio, -87.85, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-44.13
Free Cash Flow per Share-44.13
Cash per Share2.94
Operating Cash Flow Sales Ratio-87.85
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-92.97
Short Term Coverage Ratio-92.97

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 1.30%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing. An interest coverage of 2.29 indicates its ability to manage interest expenses.

Debt Ratio1.30%
Debt Equity Ratio0.02
Total Debt to Capitalization1.52%
Interest Coverage2.29
Cash Flow to Debt Ratio-92.97
Company Equity Multiplier1.19

Per Share Data

Net income per share, -14.80, reflects the portion of profit attributed to each share. The book value per share, 13.15, represents the net asset value distributed per share, while the tangible book value per share, 5.22, excludes intangible assets.

Net Income Per Share-14.80
Book Value Per Share13.15
Tangible Book Value Per Share5.22
Shareholders Equity Per Share13.15
Interest Debt Per Share0.20

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -100.00%, indicates top-line expansion, while the gross profit growth, 100.00%, reveals profitability trends. EBIT growth, 77.36%, and operating income growth, 77.36%, offer insights into operational profitability progression. The net income growth, 72.60%, showcases bottom-line expansion, and the EPS growth, 49.19%, measures the growth in earnings per share.

Revenue Growth-100.00%
Gross Profit Growth100.00%
EBIT Growth77.36%
Operating Income Growth77.36%
Net Income Growth72.60%
EPS Growth49.19%
EPS Diluted Growth49.19%
Weighted Average Shares Growth-46.06%
Weighted Average Shares Diluted Growth-46.06%
Operating Cash Flow Growth-32.57%
Free Cash Flow Growth-6.33%
5-Year Revenue Growth per Share-100.00%
3-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share99.25%
5-Year Operating CF Growth per Share92.96%
3-Year Operating CF Growth per Share-45.48%
10-Year Net Income Growth per Share99.55%
5-Year Net Income Growth per Share94.88%
3-Year Net Income Growth per Share45.73%
10-Year Shareholders Equity Growth per Share-99.34%
5-Year Shareholders Equity Growth per Share-85.68%
3-Year Shareholders Equity Growth per Share-76.43%
Receivables Growth-90.19%
Inventory Growth-742.59%
Asset Growth22.08%
Book Value per Share Growth244.00%
Debt Growth-98.43%
R&D Expense Growth-84.57%
SGA Expenses Growth-47.09%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 919,593.538, captures the company's total value, considering both debt and equity. Income quality, 2.98, assesses the reliability of reported earnings.

Enterprise Value919,593.538
Income Quality2.98
Intangibles to Total Assets50.61%
Graham Number66.16
Return on Tangible Assets-191.29%
Graham Net Net-1.22
Working Capital334,240
Tangible Asset Value2,565,036
Net Current Asset Value-12,388
Average Receivables418,667.5
Average Payables2,590,525.5
Average Inventory-31,589.5

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.04, and the price to book ratio, 0.04, reflect the market's valuation relative to the company's book value. The price to sales ratio, 28.88, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.33, and price to operating cash flows, -0.03, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.04
Price to Book Ratio0.04
Price to Sales Ratio28.88
Price Cash Flow Ratio-0.03
Enterprise Value Multiple0.69
Price Fair Value0.04
Price to Operating Cash Flow Ratio-0.03
Price to Free Cash Flows Ratio-0.33
Price to Tangible Book Ratio0.22
Enterprise Value Over EBITDA-0.68
EV to Operating Cash Flow-0.08
Earnings Yield-505.80%
Free Cash Flow Yield-800.86%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Altamira Therapeutics Ltd. (CYTO) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.046 in 2024.

What is the ticker symbol of Altamira Therapeutics Ltd. stock?

The ticker symbol of Altamira Therapeutics Ltd. stock is CYTO.

What is company IPO date?

IPO date of Altamira Therapeutics Ltd. is 2014-08-06.

What is company current share price?

Current share price is 1.500 USD.

What is stock market cap today?

The market cap of stock today is 3360360.000.

What is PEG ratio in 2024?

The current -0.002 is -0.002 in 2024.

What is the number of employees in 2024?

In 2024 the company has 10.